BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 12464116)

  • 1. Dopamine agonists and neuroprotection in Parkinson's disease.
    Schapira AH
    Eur J Neurol; 2002 Nov; 9 Suppl 3():7-14. PubMed ID: 12464116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
    Radad K; Gille G; Rausch WD
    Pharmacol Rep; 2005; 57(6):701-12. PubMed ID: 16382188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of dopamine agonists in Parkinson's disease.
    Lange KW
    Drugs Aging; 1998 Nov; 13(5):381-9. PubMed ID: 9829165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD; Jankovic J
    Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ropinirole and pramipexole, the new agonists.
    Hobson DE; Pourcher E; Martin WR
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S27-33. PubMed ID: 10451757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection in idiopathic Parkinson's disease.
    Reichmann H
    J Neurol; 2002 Oct; 249 Suppl 3():III/21-3. PubMed ID: 12522567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine agonist monotherapy in Parkinson's disease.
    Clarke CE; Guttman M
    Lancet; 2002 Nov; 360(9347):1767-9. PubMed ID: 12480442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of pramipexole and its clinical utility in Parkinson's disease.
    Biglan KM; Holloway RG
    Expert Opin Pharmacother; 2002 Feb; 3(2):197-210. PubMed ID: 11829733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
    Bennett JP; Piercey MF
    J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do dopamine agonists or levodopa modify Parkinson's disease progression?
    Marek K; Jennings D; Seibyl J
    Eur J Neurol; 2002 Nov; 9 Suppl 3():15-22. PubMed ID: 12464117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
    Etminan M; Samii A; Takkouche B; Rochon PA
    Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
    Etminan M; Gill S; Samii A
    Drug Saf; 2003; 26(6):439-44. PubMed ID: 12688834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole].
    Kohno Y; Takeuchi S
    Nihon Yakurigaku Zasshi; 2004 Jun; 123(6):429-40. PubMed ID: 15170083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.